Andreas Halvorsen Discloses Stake In Urovant Sciences (Forbes.com)
Andreas Halvorsen’s Viking Global Investors disclosed Thursday that it holds a 75.6% stake in urologic biopharmaceutical company Urovant Sciences Ltd. through its private backing of the company’s parent. Halvorsen made the holding known because Urovant went public on Oct. 1. The company originated as one of 13 “Vants” developed by umbrella owner Roivant Sciences. Each “Vant” focuses on research, development and commercialization of treatments for a specified disease. Founded by Vivek Ramaswamy in 2014, the Switzerland-based Riovant often acquires promising drugs discarded by larger biopharmaceutical companies.
Is Bill Ackman About to Go Activist Investor on Starbucks? (The Motley Fool)
For anyone who thinks that Starbucks’ (NASDAQ:SBUX) long growth arc has started to level out, there’s a billionaire who disagrees, and he’s putting his investors’ money where his mouth is. Bill Ackman‘s hedge fund, Pershing Square Capital Management, has taken a $900 million stake in the coffeehouse chain, and he sees the stock doubling in the next three years.
Luis Louro / shutterstock.com
Detour Gold Says Hedge Fund Paulson Rejected its Settlement Offer (Reuters)
Oct 12 (Reuters) – Canadian gold miner Detour Gold Corp said on Friday that its settlement offer regarding management changes, which included a plan to appoint a new chief executive officer, was rejected by hedge fund Paulson & Co. The settlement would have resulted in almost half of its board being refreshed in six weeks, with interim CEO Michael Kenyon stepping down before the next annual general meeting.
Sears Has Complicated Problems (Bloomberg.com)
What if Eddie Lampert hadn’t done all the stuff? Like, he bought some Kmart unsecured debt in 2002, became its biggest shareholder out of bankruptcy, and merged it with Sears to form Sears Holdings Corp. in 2004. Then he embarked on years of financial engineering, spinoffs, loans, restructurings and what have you to extract value and try to keep Sears afloat, ultimately becoming its chief executive officer and (through his hedge fund ESL Investments Inc.) its largest shareholder and most interesting creditor. There are signs that that might be coming to an end.
Insider Buying: Merck & Co., Inc. (MRK) Major Shareholder Acquires $9,999,990.00 in Stock (PressOracle.com)
Merck & Co., Inc. (NYSE:MRK) major shareholder Merck & Co., Inc. acquired 666,666 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The shares were bought at an average cost of $15.00 per share, for a total transaction of $9,999,990.00. The transaction was disclosed in a document filed with the SEC.
Insider Buying: Arvinas Inc (ARVN) Director Buys 40,000 Shares of Stock (FairFieldCurrent.com)
Arvinas Inc (NASDAQ:ARVN) Director Bradley Albert Margus bought 40,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was purchased at an average cost of $16.00 per share, with a total value of $640,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission.
Insider Buying: Y-mAbs Therapeutics (NASDAQ:YMAB) Director Purchases 500,000 Shares of Stock (MareaInformativa.com)
Y-mAbs Therapeutics (NASDAQ:YMAB) Director James Healy bought 500,000 shares of the company’s stock in a transaction dated Friday, September 21st. The stock was purchased at an average price of $16.00 per share, with a total value of $8,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission.
Insider Selling: Alphabet Inc (NASDAQ:GOOG) CEO Sells 10,000 Shares of Stock (FairFieldCurrent.com)
Alphabet Inc (NASDAQ:GOOG) CEO Sundar Pichai sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 19th. The shares were sold at an average price of $1,160.42, for a total value of $11,604,200.00. Following the sale, the chief executive officer now directly owns 546 shares of the company’s stock, valued at $633,589.32. The transaction was disclosed in a filing with the SEC.
Insider Selling: Lazydays Holdings Inc (NASDAQ:LAZY) Director Sells 27,541 Shares of Stock (XNewsPress.com)
Lazydays Holdings Inc (NASDAQ:LAZY) Director B. Luke Weil sold 27,541 shares of the company’s stock in a transaction dated Wednesday, September 19th. The stock was sold at an average price of $8.07, for a total transaction of $222,255.87. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
